Aging, Lipoatrophy, Wrinkles
Conditions
Keywords
Autologous Adult Stem Cell, Adipose Derived Stem Cell, Stromal Vascular Fraction, SVF, Antria, Shah Rahimian, Leonard Maliver, David Bizousky, Rahul Gore, Lee Quist, Dudley McNitt
Brief summary
The primary purpose of this study is to demonstrate the safety of injecting the Stromal Vascular Fraction (SVF) \[containing Adipose Derived Stem Cells (ADSCs)\] enriched fat grafts into regions of the face that require enhancement. The safety of SVF will be evaluated throughout the course of the study phase through the assessment of laboratory values, physical examinations, adverse events, safety phone calls etc.
Interventions
BIOLOGICALSVF
Sponsors
Antria
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female or Male, Age 18 years or older 2. Subjects that are scheduled for liposuction and facial fat grafting procedures for cosmetic purposes 3. Facial volume defects which could be treated with a total graft volume of between 1mL and 50mL 4. BMI between and including 23 and 28 5. Able to understand and provide written and verbal informed consent
Exclusion criteria
1. Currently taking or have taken NSAIDs within last two weeks or corticosteroids within the last six weeks prior to screening 2. Diagnosis of any of the following medical conditions: * Active malignancy (diagnosed within 5 years), except for treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm * Active infection * Type I or Type II Diabetes 3. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, dementia, and/or otherwise considered by the Investigator to be unlikely to complete the study) 4. Subjects with a known drug or alcohol dependence within the past 12 months as judged by the Investigator 5. Subjects with major illnesses involving the renal, hepatic, cardiovascular, and/or nervous systems 6. Subjects with elevated kidney and/or liver functions 7. Any other disease condition or laboratory results that in the opinion of the investigator may be clinically significant and render the subject inappropriate for the study procedure(s), may alter the accuracy of study results, or increase risk for subjects. 8. Subjects with life-expectancies less than 9 months 9. Subjects with known collagenase allergies 10. Subjects with idiopathic or drug-induced coagulopathy 11. Pregnant females 12. On radiotherapy or chemotherapy agents 13. Taking strong CYP450 inhibitors such as protease inhibitors (ritonavir, indinavir, nelfinavir, saquinavir), macrolide antibiotics (clarithromycin, telithromycin), chloramphenicol, azole antibiotics (ketoconazole, itraconazole) and nefazodone. 14. Subjects with a history of keloids or hypertrophic scar formations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety of the administration of a concentrated SVF-enriched fat graft by monitoring the number and types of adverse events, and via physical examinations, vital signs, 12-lead ECGs, blood draws (CBC/LFT/BMP), and urinalysis. | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| To demonstrate the efficacy of the addition of autologous SVF isolated via Antria Cell Preparation Process by observing graft survival time, volume, and quality of facial re-contouring | 6 months |
Countries
United States
Outcome results
None listed